Skip to main content

Table 4 Recombinant proteins produced in BEV for the development of new drugs or repurposing the existing drugs for COVID-19

From: Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review

Proteins Modifications Host Cells Purification Method Specific Applications References
Nsp12 Cleavage site and peptide tags added. High Five Size exclusion chromatography In vitro polymerase inhibition assay [113]
Nsp12, spike protein and receptor binding domain Cleavage site changed. Trimerization domain, sequence motifs and peptide tags added. Codon optimization. High Five Affinity and size exclusion chromatography Surface plasmon resonance (SPR) [113,114,115]
RNA-dependent RNA polymerase (RdRp) complexes (nsp5, nsp7, nsp8, nsp10, nsp12 and nsp14) Peptide tags, cleavage site, linker and sequence motifs added. Codon optimization. Sf9 Affinity and size exclusion chromatography RNA synthesis assay [116,117,118,119,120,121,122]
Nsp13 Peptide tags added. Codon optimization. Sf9 Affinity chromatography Helicase assay [123]
S1 No modification. Sf9/Tnao38 Affinity chromatography Platelet adhesion assay, In vitro thrombus formation and Flow cytometry measurement of fibrinogen binding. [124]
Nsp9 Peptide tags added. Codon optimization. Sf9 Affinity chromatography Gel based nsp9 cleavage assay [125]
papain-like protease (PLpro) Peptide tags added. Codon optimization. Sf9 Not mentioned Protease assay [126]
Spike protein and receptor binding domain A trimerization domain added. Cleavage site added. High Five Not mentioned ELISA [115]